Vanda Pharmaceuticals (VNDA +4.8%) initiates a
Phase 3 clinical trial, ODYSSEY VLY-686-3501, evaluating tradipitant,
on top of standard of care treatment, in severely ill COVID-19 patients
with acute respiratory distress syndrome.
The 300-subject study will begin in New York-area hospitals.
Tradipitant works by blocking the neurokinin-1
receptor (NK1R) that is involved in a range of neuroinflammatory
processes that leads to significant lung injury.
https://seekingalpha.com/news/3557934-vanda-pharmaceuticals-launches-study-of-tradipitant-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.